LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

Kodu・Aktsiate loetelu・Pulse Biosciences Inc

Pulse Biosciences Inc

Avatud

SektorTervishoid

27.22 16.87

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

23.49

Max

27.87

Põhinäitajad
By Trading Economics
Sissetulek	2M -17M
Müük	137K 401K
Aktsiakasum	-0.241
Kasumimarginaal	-6,603.409
Töötajad	116
EBITDA	-1.4M -19M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+25.21% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-238M 1.3B
Eelmine avamishind	10.35
Eelmine sulgemishind	27.22

Uudiste sentiment

By Acuity

50%

162 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

16.59 / 17.17 Toetus ja vastupanu

Pulse Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2026, 22:54 UTC

Tulu

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13. mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13. mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13. mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13. mai 2026, 23:17 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13. mai 2026, 23:16 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13. mai 2026, 23:15 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13. mai 2026, 23:14 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13. mai 2026, 23:02 UTC

Market Talk

Tulu

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13. mai 2026, 22:59 UTC

Market Talk

Tulu

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13. mai 2026, 22:24 UTC

Tulu

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13. mai 2026, 22:23 UTC

Tulu

Xero FY International Organic Revenue Growth 25%>XRO.AU

13. mai 2026, 22:23 UTC

Tulu

Xero FY International Revenue Growth 47%>XRO.AU

13. mai 2026, 22:22 UTC

Tulu

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13. mai 2026, 22:19 UTC

Tulu

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13. mai 2026, 22:19 UTC

Tulu

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13. mai 2026, 22:18 UTC

Tulu

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13. mai 2026, 22:16 UTC

Tulu

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13. mai 2026, 22:15 UTC

Tulu

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13. mai 2026, 22:15 UTC

Tulu

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13. mai 2026, 22:13 UTC

Tulu

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13. mai 2026, 22:12 UTC

Tulu

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13. mai 2026, 22:11 UTC

Tulu

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13. mai 2026, 22:11 UTC

Tulu

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13. mai 2026, 22:10 UTC

Tulu

Xero Did Not Declare a Dividend>XRO.AU

13. mai 2026, 22:10 UTC

Tulu

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13. mai 2026, 22:09 UTC

Tulu

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13. mai 2026, 22:00 UTC

Tulu

Cisco to Shed Jobs for All-In AI Push -- Update

13. mai 2026, 21:11 UTC

Tulu

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Pulse Biosciences Inc Prognoos

Hinnasiht

By TipRanks

25.21% tõus

12 kuu keskmine prognoos

Keskmine 30 USD 25.21%

Kõrge 30 USD

Madal 30 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Pulse Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Pulse Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

16.59 / 17.17Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

162 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.